Monitoring the immune competence of cancer patients to predict outcome.
A new era of cancer immunotherapy has brought not only successful cancer vaccines but also immunomodulators, such as those that target checkpoint blockade in order to induce endogenous host immune responses. However, the immune system of cancer patients can be compromised through multiple means, including immune suppression by the tumor and by prior therapies such as chemotherapy and radiation. Therefore, a comprehensive means of assessing patient immunocompetence would seem helpful for determining whether patients are ready to benefit from immunotherapy, and perhaps even which immunotherapy might be most appropriate for them. Unfortunately, there are no standardized tests for immune competence, nor is there agreement on what to measure and what will be predictive of outcome. In this review, we will discuss the technologies and assays that might be most useful for this purpose. We argue for a comprehensive approach that should maximize the chances of developing predictive biomarkers for eventual clinical use.
Institute for Immunity, Transplantation, and Infection, Stanford University School of Medicine, Fairchild Science Building, 299 Campus Drive, Stanford, CA, 94305-5124, USA.
Serena
S
Chang
Holbrook
H
Kohrt
Holden T
HT
Maecker
D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015166:Monitoring, Immunologic / Q000379:methods; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011237:Predictive Value of Tests; D016896:Treatment Outcome